Characteristics of international drug regulatory regimes

August 14, 2017, University of Basel

The regulatory requirements for the approval of new drugs vary greatly internationally in regards to the resources allocated to the authorities, the evaluation periods for approval and the fees for the pharmaceutical companies. This reports a study of the European Center of Pharmaceutical Medicine at the University of Basel. The results were published in the journal Nature Reviews Drug Discovery.

The researchers compared the regulatory authorities responsible for approving drugs and medical products in 12 countries, among them, for example, Swissmedic in Switzerland and the U.S. Food and Drug Administration (FDA). The results show that international encounter very different regional requirements.

Depending on the country, identical products are being evaluated not only according to different standards and processes to verify their effectiveness and safety, but certain aspects are also being reviewed and assessed multiple times and in various ways.

Harmonization could increase efficiency

The regulatory hurdles for approval (fees, studies, evaluation periods, etc.) are known to be a significant time factor in the global development. Different approval requirements prolong the time until the market entry of new, innovative drugs which also impacts their price. The study thus shows that a harmonization of these approval requirements and processes could significantly improve efficiency.

"Patients would profit especially since would be available faster and at lower prices," comments Prof. Dr. Thomas D. Szucs from the European Center of Pharmaceutical Medicine at the University of Basel. "This suggests that companies and authorities should strengthen their international collaboration and communicate better with each other."

With their study, the researchers hope to contribute to higher cost efficiency in the development of drugs and shorter authorization processes.

Explore further: Drug access delays due to pharmaceutical companies not Health Canada

More information: Anand B. Jain et al. Regulatory watch: Structural and procedural characteristics of international regulatory authorities, Nature Reviews Drug Discovery (2017). DOI: 10.1038/nrd.2017.135

Related Stories

Drug access delays due to pharmaceutical companies not Health Canada

May 12, 2014
Access to new prescription drugs in Canada is delayed by pharmaceutical company submissions to Health Canada rather than by a longer approval-processing time, according to an analysis published in CMAJ (Canadian Medical Association ...

Drug research and development more efficient than expected

February 27, 2015
Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

FDA addresses concerns on approval of drugs to treat chronic hepatitis C

June 2, 2015
Treatment options for chronic hepatitis C, a serious and life-threatening infection, have improved substantially and several new regimens with shorter durations and improved efficacy and safety profiles are now available.

FDA approves drugs more quickly than peer agency in Europe: study

April 5, 2017
The U.S. Food and Drug Administration (FDA) reviews and approves new medicines in a shorter timeframe than its peer agency in Europe, the European Medicines Agency (EMA), says a Yale researcher. This finding, which comes ...

Recommended for you

Certain teens more likely to get hooked on opioids

March 12, 2018
(HealthDay)—Teenagers with any mental health problem are more prone to painkiller dependence after receiving a prescription opioid, a new study finds.

Prescription opioids fail rigorous new test for chronic pain

March 6, 2018
A yearlong study offers rigorous new evidence against using prescription opioids for chronic pain.

Study suggests failed osteoarthritis drug could help treat opioid addiction

February 27, 2018
A new study from Indiana University suggests that a drug proven safe for use in people may prevent opioid tolerance and physical dependence when used in combination with opioid-based pain medications.

Complex inhalers prevent patients from taking medicine

February 23, 2018
Respiratory disease patients with arthritis could struggle to manage their conditions because their inhalers are too fiddly for them to use, University of Bath research has found.

Opioid abuse leads to heroin use and a hepatitis C epidemic, researcher says

February 22, 2018
Heroin is worse than other drugs because people inject it much sooner, potentially resulting in increased risk of injection-related epidemics such as hepatitis C and HIV, a Keck School of Medicine of USC study shows.

Opioid addiction treatment behind bars reduced post-incarceration overdose deaths in RI

February 14, 2018
A treatment program for opioid addiction launched by the Rhode Island Department of Corrections was associated with a significant drop in post-incarceration drug overdose deaths and contributed to an overall drop in overdose ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.